Anabolic therapy of osteoporosis

被引：2
作者：
Fernández-García, DF [1 ]
Alonso, G [1 ]
Muñoz-Torres, M [1 ]
机构：
[1] Hosp Univ San Cecilio, Unidad Metab Oseo, Serv Endocrinol & Nutr, Granada, Spain
来源：
MEDICINA CLINICA | 2005年 / 125卷 / 09期
关键词：
osteoporosis; anabolic therapies; strontium; parathyroid hormone;
D O I：
10.1157/13078782
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pharmacological treatment of osteoporosis is based mainly on antiresorptive agents. However, there have been recently developed a group of drugs whose mechanism of action is the direct stimulation of bone formation: these drugs are named bone anabolic therapies. Among these compounds are fluoride, growth hormone (GH), insulin-like growth factor type I (IGF-I) and statins. Two further agents with major evidences of efficacy include strontium ranelate and parathyroid hormone (PTH) and its fragments. The present work reviews the current evidences of anabolic agents used in the treatment of osteoporosis.
引用
收藏
页码：341 / 345
页数：5
相关论文
共 68 条
  • [51] Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass:: a randomized, controlled trial
    Reginster, JY
    Felsenberg, D
    Pavo, I
    Stepan, J
    Payer, J
    Resch, H
    Glüer, CC
    Mühlenbacher, D
    Quail, D
    Schmitt, H
    Nickelsen, T
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 (09) : 741 - 749
  • [52] The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis - A randomized, controlled trial
    Reginster, JY
    Meurmans, L
    Zegels, B
    Rovati, LC
    Minne, HW
    Giacovelli, G
    Taquet, AN
    Setnikar, I
    Collette, J
    Gosset, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) : 1 - +
  • [53] Strontium ranelate in osteoporosis
    Reginster, JY
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (21) : 1907 - 1916
  • [54] Reginster JY, 1998, ARTHRITIS RHEUM, V41, pS129
  • [55] REGINSTER JY, 2001, J BONE MINER RES S1, V16, pF400
  • [56] Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial
    Reid, IR
    Hague, W
    Emberson, J
    Baker, J
    Tonkin, A
    Hunt, D
    MacMahon, S
    Sharpe, N
    [J]. LANCET, 2001, 357 (9255) : 509 - 512
  • [57] REJNMARK L, 2001, J BONE MINER RES S1, V16, pA411
  • [58] EFFECT OF FLUORIDE TREATMENT ON THE FRACTURE RATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    RIGGS, BL
    HODGSON, SF
    OFALLON, WM
    CHAO, EYS
    WAHNER, HW
    MUHS, JM
    CEDEL, SL
    MELTON, LJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (12) : 802 - 809
  • [59] RIGGS BL, 1994, J BONE MINER RES, V9, P265
  • [60] Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate
    Ringe, JD
    Dorst, A
    Kipshoven, C
    Rovati, LC
    Setnikar, I
    [J]. OSTEOPOROSIS INTERNATIONAL, 1998, 8 (01) : 47 - 52
1234567